Algorithm Change Protocols in the Regulation of Adaptive Machine Learning-Based Medical Devices.

algorithm change protocol artificial intelligence health care healthcare machine learning regulation regulatory framework

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
26 10 2021
Historique:
received: 19 05 2021
accepted: 22 09 2021
revised: 23 08 2021
entrez: 26 10 2021
pubmed: 27 10 2021
medline: 29 10 2021
Statut: epublish

Résumé

One of the greatest strengths of artificial intelligence (AI) and machine learning (ML) approaches in health care is that their performance can be continually improved based on updates from automated learning from data. However, health care ML models are currently essentially regulated under provisions that were developed for an earlier age of slowly updated medical devices-requiring major documentation reshape and revalidation with every major update of the model generated by the ML algorithm. This creates minor problems for models that will be retrained and updated only occasionally, but major problems for models that will learn from data in real time or near real time. Regulators have announced action plans for fundamental changes in regulatory approaches. In this Viewpoint, we examine the current regulatory frameworks and developments in this domain. The status quo and recent developments are reviewed, and we argue that these innovative approaches to health care need matching innovative approaches to regulation and that these approaches will bring benefits for patients. International perspectives from the World Health Organization, and the Food and Drug Administration's proposed approach, based around oversight of tool developers' quality management systems and defined algorithm change protocols, offer a much-needed paradigm shift, and strive for a balanced approach to enabling rapid improvements in health care through AI innovation while simultaneously ensuring patient safety. The draft European Union (EU) regulatory framework indicates similar approaches, but no detail has yet been provided on how algorithm change protocols will be implemented in the EU. We argue that detail must be provided, and we describe how this could be done in a manner that would allow the full benefits of AI/ML-based innovation for EU patients and health care systems to be realized.

Identifiants

pubmed: 34697010
pii: v23i10e30545
doi: 10.2196/30545
pmc: PMC8579211
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e30545

Informations de copyright

©Stephen Gilbert, Matthew Fenech, Martin Hirsch, Shubhanan Upadhyay, Andrea Biasiucci, Johannes Starlinger. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 26.10.2021.

Références

NPJ Digit Med. 2020 Sep 11;3:118
pubmed: 32984550
Science. 2019 Dec 6;366(6470):1202-1204
pubmed: 31806804
Lancet. 2013 Feb 16;381(9866):557-64
pubmed: 23253623
Lancet Digit Health. 2021 Mar;3(3):e195-e203
pubmed: 33478929
Health Econ Policy Law. 2021 Jan;16(1):51-63
pubmed: 32631465
J Law Biosci. 2020 Apr 11;7(1):lsaa002
pubmed: 34221415
JAMA Intern Med. 2021 Aug 1;181(8):1065-1070
pubmed: 34152373
Lancet Digit Health. 2020 Jul;2(7):e376-e379
pubmed: 33328096
Lancet Digit Health. 2021 Jun;3(6):e337-e338
pubmed: 33933404
BMJ. 2020 Mar 25;368:m689
pubmed: 32213531
J Med Internet Res. 2021 Jun 16;23(6):e26514
pubmed: 34132641
Lancet. 2019 Jul 6;394(10192):9-11
pubmed: 30935732
Sci Transl Med. 2016 May 4;8(337):337ra64
pubmed: 27147588
J Am Med Inform Assoc. 2021 Mar 18;28(4):677-684
pubmed: 33447854
BMJ Health Care Inform. 2021 Apr;28(1):
pubmed: 33853863
Nat Med. 2021 Apr;27(4):582-584
pubmed: 33820998

Auteurs

Stephen Gilbert (S)

Ada Health GmbH, Berlin, Germany.
Else Kröner-Fresenius Center for Digital Health, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Matthew Fenech (M)

Ada Health GmbH, Berlin, Germany.
Una Health GmbH, Berlin, Germany.

Martin Hirsch (M)

Ada Health GmbH, Berlin, Germany.
Institute for AI in Medicine, University Hospital of Giessen and Marburg, Marburg, Germany.

Shubhanan Upadhyay (S)

Ada Health GmbH, Berlin, Germany.

Andrea Biasiucci (A)

Laboratory for Investigative Neurophysiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
confinis ag, Sursee, Switzerland.

Johannes Starlinger (J)

Howto Health GmbH, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH